202 related articles for article (PubMed ID: 30148829)
1. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.
Gandolfi S; Vekstein C; Laubach JP; O'Brien A; Masone K; Munshi NC; Anderson KC; Richardson PG
Clin Adv Hematol Oncol; 2018 Aug; 16(8):564-574. PubMed ID: 30148829
[TBL] [Abstract][Full Text] [Related]
2. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA; Tacchetti P; Pantani L; Gamberi B; Tosi P; Rocchi S; Cellini C; Ronconi S; Pezzi A; Mancuso K; Rizzello I; Caratozzolo I; Martello M; Dozza L; Cavo M; Zamagni E
Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
[TBL] [Abstract][Full Text] [Related]
3. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
Richardson PG; Laubach JP; Munshi NC; Anderson KC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):255-61. PubMed ID: 25696864
[TBL] [Abstract][Full Text] [Related]
4. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
5. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.
Merz M; Dechow T; Scheytt M; Schmidt C; Hackanson B; Knop S
Ann Hematol; 2020 Aug; 99(8):1709-1725. PubMed ID: 32296915
[TBL] [Abstract][Full Text] [Related]
6. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
[TBL] [Abstract][Full Text] [Related]
7. Evolving strategies in the initial treatment of multiple myeloma.
Rosenbaum C; Jasielec J; Laubach J; Paba Prada C; Richardson P; Jakubowiak AJ
Semin Oncol; 2013 Oct; 40(5):592-601. PubMed ID: 24135404
[TBL] [Abstract][Full Text] [Related]
8. Management of relapsed multiple myeloma after autologous stem cell transplant.
Holstein SA; Richardson PG; Laubach JP; McCarthy PL
Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
[TBL] [Abstract][Full Text] [Related]
9. The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.
Gay F; Cavallo F; Palumbo A
Drugs; 2015 Mar; 75(4):367-75. PubMed ID: 25764394
[TBL] [Abstract][Full Text] [Related]
10. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.
Cornell RF; Kassim AA
Bone Marrow Transplant; 2016 Apr; 51(4):479-91. PubMed ID: 26726946
[TBL] [Abstract][Full Text] [Related]
11. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
[TBL] [Abstract][Full Text] [Related]
12. The future of autologous stem cell transplantation in myeloma.
van Rhee F; Giralt S; Barlogie B
Blood; 2014 Jul; 124(3):328-33. PubMed ID: 24894774
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
14. Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy.
Mo CC; Hartley-Brown MA; Midha S; Richardson PG
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136255
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma.
Wildes TM; Finney JD; Fiala M; Gao F; Vij R; Stockerl-Goldstein K; Carson KR; Mikhael J; Colditz G
Bone Marrow Transplant; 2015 Aug; 50(8):1075-82. PubMed ID: 25961765
[TBL] [Abstract][Full Text] [Related]
16. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
17. Evolving role of stem cell transplantation in multiple myeloma.
Harousseau JL; Moreau P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
[TBL] [Abstract][Full Text] [Related]
18. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
19. Role of stem cell transplant and maintenance therapy in plasma cell disorders.
McCarthy PL; Holstein SA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):504-511. PubMed ID: 27913522
[TBL] [Abstract][Full Text] [Related]
20. All transplantation-eligible patients with myeloma should receive ASCT in first response.
Moreau P; Attal M
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):250-4. PubMed ID: 25696863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]